TOMORROW'S TRIALS

As variations of the overarching theme of non-oncological off-label drug combinations (“hard” repurposing) for which CUSP9v3 may serve as a potential paradigm, we have devised several additional neuro-oncological concepts for prospective evaluation. These concepts either focus on specific neuro-oncological aspects or, in case of the EIS, MTZ and MDACT regimens (see below), are associated with lesser complexity and decreased financial costs compared to CUSP9v3, rendering them potential alternatives under certain conditions.

Contact Us
Concomitant Radiochemotherapy
ATCG

A new treatment opportunity for DIPG and diffuse midline gliomas
(5aai regimen)

ATCG

Augmentation of 5-aminolevulinic acid treatment (CAALA regimen)

ATCG

Blocking epithelial-to-mesenchymal transition in glioblastoma (EIS regimen)

ATCG

A new principle of adjunctive cancer treatment using combinations of multiple repurposed drugs
(MDACT regimen)

ATCG

Toward a noncytotoxic glioblastoma therapy
(MTZ regimen)

ATCG

A potential dexamethasone-sparing regimen for glioblastoma (SEC regimen)

ATCG

Glioblastoma treatment using perphenazine to block the subventricular zone's tumor trophic functions